Phase III pediatric clinical trials now set the pace in a market expected to reach USD 35.64 billion by 2035. The push comes from more funding, new regulatory incentives, and a steady stream of age-specific therapies. This shift is already visible. North America is on track for over USD 11.82 billion. Europe is close behind at USD 10.13 billion. Drug companies are ramping up pediatric research as chronic, genetic, and infectious diseases rise among children.
According to an independent academic review, the annual number of new pediatric clinical trials peaked at 608 in 2017 but dropped sharply to just 147 by 2025, signaling a slowdown in new trial initiations.
Regulatory rules are not just background. They shape the market. In the U.S., the Best Pharmaceuticals for Children Act (BPCA, 2002) and the Pediatric Research Equity Act (PREA, 2003) set the foundation. The 2020 RACE for Children Act raised the bar for pediatric oncology drugs. It requires studies on dosing, safety, and early efficacy, even for rare cancers. Details are in a Springer regulatory review. Europe has its own strict rules. The Pediatric Regulation (EC) No. 1901/2006 demands a Pediatric Investigation Plan (PIP) approved by the EMA. For off-patent drugs, the PUMA pathway gives "8+2" years of market protection, partial fee waivers, and a single process to boost pediatric development.
These laws are driving real trial activity. Infectious diseases and oncology lead the way. Oncology is now the fastest-growing area. Money is flowing into targeted therapies, immunotherapies, and precision drugs for childhood cancers. Industry and academic sources agree: regulatory demands and incentives—not just market need—are pushing more pediatric research. In oncology, rules for targeted drugs have directly increased the number of studies.
Despite the growing need, only about 4% of federal cancer research funding in the U.S. is allocated to pediatric cancers, leaving specialized consortia and hospitals vulnerable to funding cuts and delays in clinical trials.
Major contract research organizations are fighting for market share. IQVIA Holdings Inc., ICON plc, Laboratory Corporation of America Holdings (Labcorp), Syneos Health, Parexel International Corporation, and Medpace Holdings, Inc. are key players. Recent milestones stand out. Merck reported positive topline results for clesrovimab in RSV prevention. Novartis released new data for Zolgensma in older children with spinal muscular atrophy. The sector is moving fast.
The unmet need is huge. One in ten children worldwide has a disability or chronic illness that needs treatment. Pediatric-specific trials are essential. Phase III trials now hold 49% of the market. Phase II is growing fastest. Infectious diseases are still the largest focus, but oncology is catching up. Treatment studies lead, but observational designs are growing fastest. The field is shifting toward more evidence, not just new drugs.
Advanced therapies are gaining ground. Pediatric gene and cell therapy trials now follow trends seen in adult oncology. This was covered in our reported earlier on first-in-human CAR-T studies. Regulatory incentives, digital tools, and global investment are raising the bar for pediatric research.
This market does not reward complacency. The next decade will favor those who can handle complex rules, use digital tools for faster trials, and deliver strong evidence for pediatric safety and efficacy. The numbers tell part of the story. The real race is operational and scientific. It will shape the future of pediatric medicine. Only bold companies will lead.
